Tags

Type your tag names separated by a space and hit enter

No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas.
Cancer Lett. 2006 Apr 08; 235(1):136-40.CL

Abstract

Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.

Authors+Show Affiliations

Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. karen.barker@icr.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15949892

Citation

Barker, Karen T., et al. "No Evidence for Epigenetic Inactivation of Fumarate Hydratase in Leiomyomas and Leiomyosarcomas." Cancer Letters, vol. 235, no. 1, 2006, pp. 136-40.
Barker KT, Spendlove HE, Banu NS, et al. No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Lett. 2006;235(1):136-40.
Barker, K. T., Spendlove, H. E., Banu, N. S., Bridge, J. A., Fisher, C., Shipley, J., Garrett, M., Manyonda, I., & Houlston, R. S. (2006). No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters, 235(1), 136-40.
Barker KT, et al. No Evidence for Epigenetic Inactivation of Fumarate Hydratase in Leiomyomas and Leiomyosarcomas. Cancer Lett. 2006 Apr 8;235(1):136-40. PubMed PMID: 15949892.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. AU - Barker,Karen T, AU - Spendlove,Hayley E, AU - Banu,Nassera S, AU - Bridge,Julia A, AU - Fisher,Cyril, AU - Shipley,Janet, AU - Garrett,Michelle, AU - Manyonda,Isaac, AU - Houlston,Richard S, Y1 - 2005/06/08/ PY - 2005/02/13/received PY - 2005/04/09/revised PY - 2005/04/12/accepted PY - 2005/6/14/pubmed PY - 2006/6/9/medline PY - 2005/6/14/entrez SP - 136 EP - 40 JF - Cancer letters JO - Cancer Lett. VL - 235 IS - 1 N2 - Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression. SN - 0304-3835 UR - https://www.unboundmedicine.com/medline/citation/15949892/No_evidence_for_epigenetic_inactivation_of_fumarate_hydratase_in_leiomyomas_and_leiomyosarcomas_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3835(05)00391-5 DB - PRIME DP - Unbound Medicine ER -